The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology's success.
The marriage of biotechnology and the pharmaceutical industry (pharma) is predicated on an evolution in technology and product innovation. It has come as a result of advances in both the science and the business practices of the biotechnology sector in the past 30 years. Biotechnology products can be thought of as "intelligent pharmaceuticals," in that they often provide novel mechanisms of action, new approaches to disease control, higher clinical success rates, improved patient care, extended patent protection, and a significant likelihood of reimbursement. Although the first biotechnology product, insulin, was approved just 32 years ago in 1982, today there are more than 200 biotechnology products commercially available. Research has expanded to include more than 900 biotechnology products in clinical trials. Pharma is substantially engaged in both the clinical development of these products and their commercialization.
1] Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts, USA [2] University of the Pacific, Stockton, California, USA [3] MAPS 4 Biotec, Napa, California, USA.
R P
RP
Evens
Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts, USA.
K I
KI
Kaitin
D001709:Biotechnology / Q000191:economics / Q000379:methods*; D002986:Clinical Trials as Topic; D003695:Delivery of Health Care / Q000592:standards; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics; D010330:Patents as Topic; D005791:Patient Care / Q000592:standards; D012106:Research / Q000458:organization & administration*